[{"id":"4c36bc05-4f8b-4445-89c4-c81896c29440","acronym":"BioPER","url":"https://clinicaltrials.gov/study/NCT03184090","created_at":"2021-01-18T15:42:02.729Z","updated_at":"2024-07-02T16:36:08.551Z","phase":"Phase 2","brief_title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","source_id_and_acronym":"NCT03184090 - BioPER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 06/28/2017","start_date":" 06/28/2017","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 10/27/2020","study_completion_date":" 10/27/2020","last_update_posted":"2022-06-21"}]